The CEO of Aelis Farma, Pier Vincenzo Piazza, stated the company's commitment to continuing its roadmap with the aim of providing an effective treatment for cannabis addiction. BORDEAUX - Aelis Farma, a biopharmaceutical company, has announced the completion of patient recruitment for its Phase 2b clinical trial, which is investigating AEF0117, a potential treatment for cannabis use disorder  CUD . Initial results from the trial are expected by the end of the second quarter of 2024.Professor Frances Levin from Columbia University, the principal investigator of the study, expressed gratitude toward the participants and medical teams involved and highlighted the demand for treatment options for CUD.In preparation for a potential Phase 3 study, Aelis Farma has also conducted parallel toxicology studies, which have reportedly confirmed AEF0117's favorable safety profile as observed by the independent Data Safety Monitoring Board for the initial 115 patients. Additionally, Aelis Farma has an exclusive option and license agreement with Indivior PLC for the development and commercialization of AEF0117, which could lead to significant financial benefits for Aelis Farma upon successful advancement of the drug. This news is based on a press release statement from Aelis Farma.
Aelis Farma has completed patient recruitment for its Phase 2b clinical trial investigating AEF0117, a potential treatment for cannabis use disorder (CUD). Initial results are expected by the end of the second quarter of 2024.